Abstract
With the increasing prevalence of obesity and its impact on metabolic and cardiovascular diseases, more attention is now being focused on the relationship between obesity and renal function. It is now recognized that obesity enhances the progression of renal function deterioration to end-stage renal disease (ESRD) in subjects with known preexisting renal disease. In addition, obestiy is associated with a well-described glomerulopathy called focal segmental glomerulosclerosis (FSGS). Finally, and most important, through its close association with type 2 diabetes and hypertension, the two most important causes of ESRD in the United States (1), obesity is now felt to be a major risk factor for the development of chronic kidney disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
USRDS: the United States Renal Data System. Am J Kidney Dis 2003;42(6)(Suppl 5):1–230.
Jennette JC, Charles L, Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis 1987;10(6):470–472.
Bailey RR, Lynn KL, Burry AF, Drennan C. Proteinuria, glomerulomegaly and focal glomerulosclerosis in a grossly obese man with obstructive sleep apnea syndrome. Aust N Z J Med 1989;19(5):473, 474.
Valensi P, Assayag M, Busby M, Paries J, Lormeau B, Attali JR. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 1996;20(6):574–579.
Ribstein J, du Callar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension 1995;26(4):610–615.
Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001;249(6):519–526.
Liese AD, Hense HW, Doring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001;15(11):799–804.
Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59(4):1498–1509.
Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens 2003;12(2):195–200.
Hall JE. The kidney, hypertension, and obesity. Hypertension 2003;41(3 Pt 2):625–633.
Bloomfield GL, Sugerman HJ, Blocher CR, Gehr TW, Sica DA. Chronically increased intra-abdominal pressure produces systemic hypertension in dogs. Int J Obes Relat Metab Disord 2000;24(7):819–824.
Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann NY Acad Sci 1999;892:91–107.
Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001;14(11 Pt 2):304S–309S.
Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha-and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001;14(7 Pt 1):694–698.
Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995;25(4 Pt 2):893–897.
Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334(5):292–295.
Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30(3 Pt 2):619–623.
Jackson EK, Li P. Human leptin has natriuretic activity in the rat. Am J Physiol 1997;272(3 Pt 2):333–338.
Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000;49(2):293–297.
Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002;51(1):168–173.
Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998;31(1 Pt 2):409–414.
Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000;105(9):1243–1252.
Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001;37(2 Pt 2):670–676.
Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL. The concept of selective leptin resisstance: evidence from agouti yellow obese mice. Diabetes 2002;51(2):439–442.
Rahmouni K, Haynes WG, Morgan DA, Mark AL. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension 2002;39(2 Pt 2):486–490.
Emdin M, Gataldelli A, Muscelli E, et al. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 2001;103(4):513–519.
Rocchini AP. Obesity hypertension, salt sensitivity and insulin resistance. Nutr Metab Cardiovasc Dis 2000;10(5):287–294.
Hall JE. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int 1993;43(6):1402–1417.
Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998;95(5):2498–2502.
Fujiwara K, Hayashi K, Ozawa Y, Tokuyama H, Nakamura A, Saruta T. Renal protective effect of troglitazone in Wistar fatty rats. Metabolism 2000;49(10):1361–1364.
Hall JE, Brands MW, Dixon WN, Smith MJ Jr. Obesity-induced hypertension: renal function and systemic hemodynamics. Hypertension 1993;22(3):292–299.
Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001;79(1):21–29.
Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001;15(14):2727–2729.
Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [see comments]. Kidney Int 1999;56(3):860–872.
Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97(14):8015–8020.
Han DC, Isono M, Chen S, et al. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001;59(4):1315–1323.
Ballermann BJ. A role for leptin in glomerulosclerosis? Kidney Int 1999;56(3):1154, 1155.
Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002;39(1):1–11.
Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998;31(1 Pt 2):181–188.
Griffin KA, Abu-Amarah I, Picken M, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 2003;41(2):201–206.
Kurtz TW. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 2003;41(2):193–196.
Anderson PW, Zhang XY, Tian J, et al. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int 1996;50(3):745–753.
Abrass CK, Spicer D, Raugi GJ. Induction of nodular sclerosis by insulin in rat mesangial cells in vitro: studies of collagen. Kidney Int 1995;47(1):25–37.
Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319–336.
Zhou Y-T, Grayborn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784–1789.
Dwyer TM, Mizelle HL, Cockrell K, Buhner P. Renal sinus lipomatosis and body composition in hypertensive, obese rabbits. Int J Obes Relat Metab Disord 1995;19(12):869–874.
Keane WF. The role of lipids in renal disease: future challenges. Kidney Int Suppl 2000;75:S27–S31.
Lyon CJ, Law RE, Huseh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144(6):2195–2200.
Lavaud S, Poirier B, Mandet C, et al. Inflammation is probably not a prerequisite for renal interstitial fibrosis in normoglycemic obese rats. Am J Physiol Renal Physiol 2001;280(4):683–694.
Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003;307(3):854–860.
Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ. Development of hypertension in a rat model of diet-induced obesity. Hypertension 2000;35(4):1009–1015.
Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension: hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981;141(1):81–85.
Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278(5):F817–F822.
Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002;324(3):127–137.
Wesson DE, Kurtzman NA, Frommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron 1985;40(2):235–237.
Metcalf P, Baker J, Scott A, Wild C, Scragg R, Dryson E. Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem 1992;38(9):1802–1808.
Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12(6):1211–1217.
de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002;26(Suppl 4):21–24.
Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 1974;81(4):440–447.
Praga M, Morales E, Herrero JC, et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33(1):52–58.
Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med 1986;146(6):1105–1109.
Kasiske BL, Napier J. Glomerular sclerosis in patients with massive obesity. Am J Nephrol 1985;5(1):45–50.
Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16(9):1790–1798.
Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 2001;138(4):481–485.
Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60(3):1131–1140.
Zhang Z, Shahimtar S, Keane WF, et al. Importance of baseline distribution of proteinuria in renal outcome trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist (RENAAL) study. J Am Soc Nephrol 2005;16:1775–1780.
Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000;58(5):2111–2118.
Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001;37(4):720–727.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63(1):225–232.
Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003;14(4):479–487.
Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer—a quantitative review. Br J Cancer 2001;85(7):984–990.
Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000;343(18):1305–1311.
Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in over-weight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41(2):319–327.
Krebs JD, Evans S, Cooney L, et al. Changes in risk factors for cardiovascular disease with body fat loss in obese women. Diabetes Obes Metab 2002;4(6):379–387.
Metz JA, Stern JS, Kris-Etherton P, et al. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000;160(14):2150–2158.
Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36(1):20–25.
Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001;134(1):1–11.
Fagerberg B, Andersson OK, Isaksson B, Bjorntorp P. Blood pressure control during weight reduction in obese hypertensive men: separate effects of sodium and energy restriction. Br Med J (Clin Res Ed) 1984;288(6410):11–14.
Seals DR, Tanaka H, Clevenger CM, et al. Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness. J Am Coll Cardiol 2001;38(2):506–513.
Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14(6):1480–1486.
Haciyanli M, Erkan N, Bora S, Gulay H. Vertical banded gastroplasty in the Aegean region of Turkey. Obes Surg 2001;11(4):482–486.
Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study—rationale and results. Int J Obes Relat Metab Disord 2001;25(Suppl 1):S2–S4.
Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40(6):781–788.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861–869.
de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004;43(1):41–47.
Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004;43(1):48–56.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Geneidy, A., Solomon, R. (2006). Obesity and Renal Disease. In: Mantzoros, C.S. (eds) Obesity and Diabetes. Contemporary Diabetes. Humana Press. https://doi.org/10.1007/978-1-59259-985-1_18
Download citation
DOI: https://doi.org/10.1007/978-1-59259-985-1_18
Publisher Name: Humana Press
Print ISBN: 978-1-58829-538-5
Online ISBN: 978-1-59259-985-1
eBook Packages: MedicineMedicine (R0)